Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nepafenac 0.1% for Vitreous Biomarkers in RRD
NCT07162818Phase 4Completed
- Sponsor
- Universitas Indonesia
- Start
- Apr 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of nepafenac in rhegmatogenous retinal detachment (RRD), sponsored by Universitas Indonesia. Started Apr 2021; status: completed.
02
Drugs
nepafenac
03
Conditions
rhegmatogenous retinal detachment (RRD)
Beyond the preview
Go deeper on NCT07162818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07162818.